acted in THF at room temperature and the resulting mixture refluxed with 2-aminoethanol to yield alcohol 4. Mesylation of primary hydroxyl group of compound 4 and the resulting mesylate was stirred at ambient temperature to give imidazolidinylidene propanedinitrile 5 by spontaneous intramolecular cyclization. Compound 5 was then treated with 1,3-dibromopropane and introduction of piperidine to the bromide 6a yielded compound 7a. The benzyl group of compound 7a was removed to yield compound 2a (RϭH) in 85% yield. Reductive alkylation of compound 2a with acetone in presence of Na(OAc) 3 BH gave compound 2b (Rϭiso-Pr). Furthermore, as illustrated in Chart 2, compound 2a was treated with corresponding electrophiles and K 2 CO 3 in DMF to provide compounds 2d, 2e 11) and 2f. The cyclopropyl containing compound 2c was synthesized as depicted in Chart 3. Compound 5 was reacted with (3-bromopropoxy)-tert-butyldimethylsilane to give compound 9 in 90% yield. Simultaneous debenzylation and desilylation of compound 9 afforded amino alcohol 10 in 93% yield. Then, cyclopropylation of compound 10 by use of (1-ethoxycyclopropoxyl)trimethylsilane under reductive alkylation condition gave compound 11 in 70% yield. Finally, alcohol 11 was mesylated and the resulting mesylate 12 heated with excess piperidine in 1,4-dioxane to give target molecule 2c with a yield of 83%.
In order to examine the effect of the distance between two basic nitrogen atoms on human and rat H 3 R affinities, compounds 2g (Chart 1: mϭ2, nϭ0) and 2h (Chart 4: mϭ3, nϭ1) were synthesized. As shown in Chart 1, compound 2g was obtained by a method similar to that of preparation of compound 2b. Namely, 1,2-dibromoethane was used instead of 1,3-dibromopropane in step c to give compound 6b in 59% yield. Then, compound 6b was transformed to target compound 2g by addition of piperidine, debenzylation and iso-propylation. On the other hand, compound 2h was synthesized as follows. Compound 13, 9) obtained from malononitrile 5 and N- (3-hydroxypropyl) ethylenediamine, was reacted with 1-tert-butoxylcarbonyl-4-methanesulfonyloxymethylpiperidine 12) to give compound 14 with a yield of 50%. Mesylation of compound 14, and then introduction of piperidine to the mesylate afforded compound 15. Finally, the Boc protecting group was removed by TFA and the resulting amine treated with 2-iodopropane to yield compound 2h (Chart 4).
Modification of the piperidino moiety of compound 2b or 2c was performed as illustrated in Charts 3 and 5. By virtue of the use of an intermediate 12 or 17, three kinds of amines were effectively introduced in the last step to yield compounds 2i-m.
The binding assay results for compounds 2a-m in human and rat H 3 Rs are shown in Table 1 . The effects of the alkyl group R modification were analyzed first. Although compound 2a (RϭH) exhibited negligible affinities, introduction of iso-propyl (2b) and cyclo-propyl (2c) substituents at the N-1 position of a 4-piperidinyl moiety in compound 2a caused an increase in affinities for both H 3 Rs. For example, compound 2b showed six-fold and nine-fold affinity to human and rat H 3 Rs (K i ϭ0.37 nM and 0.28 nM, respectively) than those of parent compound 1. Furthermore, compound 2b showed excellent selectivity over human H 1 , H 2 and H 4 receptors (percent inhibition of hH 1 R, hH 2 R, hH 4 R at 10 mM; 20%, Ϫ12%, Ϫ4%). Compound 2c also showed high affinities to both H 3 Rs (K i ϭ0.20 nM for human and 0.23 nM for rat, respectively). In contrast to 2b and 2c, compounds 2d-f, having alkyl substituents with electron withdrawing characteristics, exhibited low affinities for human and rat H 3 Rs.
Modification of linker length (i.e. compounds 2g, 2h) caused decrease in affinity for both human and rat H 3 Rs. These results indicate that the distance between two basic nitrogen atoms is important for high affinities to both H 3 Rs.
With regard to modification of the variable amine moiety (Table 1) , compounds 2j, 2k and 2m, in which the piperidine moiety was replaced with thiomorpholine or 4-oxopiperidine, retained good affinities for human and rat H 3 Rs with K i values roughly equal to those of their parent compounds 2b and 2c. Conversely, compounds 2i and 2l possessing morpholine had less affinity for both H 3 Rs than 2b or 2c.
Compounds 2b, 2c, 2d, 2i, 2j, 2k, 2l and 2m were selected for a functional assay. 13) Among them, compounds 2b and 2c reversed NAMH-mediated inhibition of [ 3 H]-histamine release from rat forebrain synaptosomes with IC 50 values of 10.2 nM and 11.6 nM, respectively (Table 1) . Therefore, these compounds were found to be twice as potent as antagonists of rat neuronal H 3 R than compound 1. Somehow, there is a poor correlation between K i values and IC 50 values. Although the reason is not clear, remarkable differences between thioperamide (known as an inverse agonist) and proxyfan (known as a neutral antagonist) in these assays were found as shown in Table 1 . In the functional assay, thioperamide and proxyfan showed IC 50 values of 54.1 nM and 3397 nM, respectively, in spite of their similar affinities for rat H 3 Rs (K i ; 5.14 nM, 3.95 nM, respectively). These results have led to speculation that the potency of inverse agonistic activity might affect the reverse activity toward NAMH-mediated inhibition of [ 3 H]-histamine release. Further study of characterization of compounds 2 and this speculation are necessary.
In conclusion, we have developed a new series of imidazo-lidinylidene propanedinitrile based novel H 3 R ligands possessing a 1-alkylated-4-piperidinyl moiety as a conformationally restricted linker. This shows potent affinity to both human and rat H 3 Rs, some of which are proven potent antagonists at H 3 Rs in rat cortical synaptosomes. Further structural modification and pharmacological evaluation of these compounds are in progress.
Experimental 1 H-NMR spectra were obtained on a JEOL JNM-EX270 (270 MHz) instrument with chemical shifts (d) reported relative to tetramethylsilane as an internal standard. Melting points were determined on a Yanaco micro melting point apparatus and are uncorrected. Mass spectra were recorded using a MICROMASS Quattro. Elemental analyses were performed by PerkinElmer Series II CHNS/O Analyzer 2400 or Thermo Quest Flash EA1112. Column chromatography was carried out on YMC GEL SIL-60-S150. Thinlayer chromatography (TLC) was performed using 250 mm silica gel 60 glass-backed plates with F254 as indicator.
Synthesis of Compound 2a (Chart 1).
Step a To a solution of [bis(methylthio)methylene]malononitrile 3 (3.00 g, 17.6 mmol) in THF (30 ml) was added 4-amino-1-benzylpiperidine (3.59 ml, 17.6 mmol). After the mixture was stirred at room temperature for 19 h, 2-aminoethanol (0.70 ml, 11.6 mmol) was added to the solution and refluxed for a further 10 h. The resulting mixture was concentrated under reduced pressure and the residue was triturated with ethyl acetate and diisopropyl ether to give 4 (3.18 g, 58%) as a brown solid. Step b To a solution of compound 4 (1.88 g, 5.78 mmol) and triethylamine (3.38 ml, 24.3 mmol) in dichloromethane (20 ml) was added methanesulfonyl chloride (0.805 ml, 10.4 mmol). The mixture was stirred at room temperature for 69 h and diluted with brine. The mixture was extracted with chloroform. The combined organic extracts were washed with brine and dried (MgSO 4 ), filtered, and concentrated under vacuum to give compound 5 (0.705 g, 40%) as a white solid. Step c To a solution of compound 5 (0.705 g, 2.29 mmol) and K 2 CO 3 (0.475 g, 3.44 mmol) in DMF (7 ml) was added 1,3-dibromopropane (1.39 ml, 13.7 mmol) and the mixture was stirred at room temperature for 26 h. The reaction mixture was diluted with ethyl acetate and washed with brine. The combined organic extracts were dried (MgSO 4 ), filtered, and concentrated in vacuo. The residue was triturated with n-hexane to afford 6a (0.694 g, 71%) as a white solid. Step d Compound 6a (0.694 g, 1.62 mmol) was dissolved in 1,4-dioxane (7 ml), and K 2 CO 3 (0.448 g, 3.24 mmol), KI (0.269 g, 1.62 mmol) and piperidine (0.481 ml, 4.86 mmol) were added. After the solution was stirred at 80°C for 7 h, the mixture was allowed to cool to room temperature and diluted with ethyl acetate. The organic layer was washed with brine, dried (MgSO 4 ), filtered and concentrated under vacuum. The residue was recrystallized from acetone and diisopropyl ether to give 7a (360 mg, 51%) as a white solid. mp 156-158°C.
1 H-NMR (CDCl 3 ) d: 1.37-1.93 (12H, m, 3-CH 2 , 4-CH 2 and 5-CH 2 of piperidino group, 3-CH 2 and 5-CH 2 of 4-piperidinyl group, piperidino-CH 2 -CH 2 -CH 2 -), 2.08-2.22 (2H, m, 2-CH and 6-CH of 4-piperidinyl group), 2.29-2.43 (6H, m, 2-CH 2 and 6-CH 2 of piperidino group, piperidino-CH 2 -CH 2 -CH 2 -), 2.9-3.02 (2H, m, 2-CH and 6-CH of 4-piperidinyl group), 3.47-3.65 (8H, m, Ph-CH 2 -, piperidino-CH 2 -CH 2 -CH 2 -, imidazolidine ring CH 2 ϫ2), 4.21 (1H, m, piperidine 4-CH), 7.23-7.36 (5H, m, Ph).
Step e To a solution of 7a (200 mg, 0.463 mmol) in 1,2-dichloroethane (3 ml) was added 1-chloroethyl chloroformate (0.18 ml, 1.7 mmol). The mixture was refluxed for 4.5 h and concentrated in vacuo. The residue was dissolved in methanol (3 ml) and resulting solution refluxed for further 1.5 h. The resulting mixture was concentrated under reduced pressure and the residue dissolved in 1 mol/l NaOH aq. The alkaline solution was extracted with ethyl acetate twice and the combined organic layer was dried (MgSO 4 
Synthesis of Compound 2d (Chart 2).
Step a Compound 2a (78 mg, 0.23 mmol) was dissolved in DMF (2 ml), and K 2 CO 3 (190 mg, 1.38 mmol) and 1-bromo-2-fluoroethane (0.051 ml, 0.69 mmol) were added. After the solution was stirred at room temperature for 64 h, the mixture was diluted with ethyl acetate. The organic layer was washed with brine, dried (MgSO 4 ), filtered and concentrated under vacuum. The residue was purified by silica gel column chromatography, eluting with 10% 2 mol/l NH 3 -CH 3 OH/CHCl 3 to provide crude 2d, which was recrystallized from diisopropyl ether to afford pure 2d (17 mg, 19%) as a white solid. mp 56-57°C. 
Synthesis of Compounds 2e and 2f (Chart 2)
Compounds 2e and 2f were synthesized using a method similar to that for preparation of compound 2d.
Compound 2e (White Solid): mp 103-105°C (n-hexane/ethyl acetate). 1 Step b To a solution of 9 (500 mg, 1.02 mmol) in 1,2-dichloroethane (5 ml) was added 1-chloroethyl chloroformate (0.275 ml, 2.55 mmol). The mixture was refluxed for 1 h and concentrated in vacuo. The residue was dissolved in methanol (5 ml) and the solution was refluxed for further 1 h. The resulting mixture was concentrated under reduced pressure and the residue was triturated with ethyl acetate to give compound 10 (HCl salt; 0.295 g, 93%) as a white solid. Step c To a solution of 10 (720 mg, 2.31 mmol), triethylamine (0.32 ml, 2.3 mmol), acetic acid (3.96 ml) and (1-ethoxycyclopropoxy)trimethylsilane (0.93 ml, 4.6 mmol) in THF (35 ml) and methanol (0.36 ml) was added sodium cyanoborohydride (310 mg, 4.62 mmol) and the mixture was stirred at 60°C for 3 h. After the reaction was completed, the solution was diluted with H 2 O (110 ml) and 2 mol/l HCl aq. and washed with ethyl acetate. The aqueous layer was neutralized with K 2 CO 3 , and then extracted with ethyl acetate. The organic extracts were washed with brine, dried (MgSO 4 ), filtered, and concentrated in vacuo. The residue triturated with n-hexane and ethyl acetate (20 : 1) to give compound 11 (510 mg, 70%) as a white solid. Step d To a solution of compound 11 (500 mg, 1.60 mmol) and triethylamine (0.89 ml, 6.41 mmol) in dichloromethane (6 ml) was added methanesulfonyl chloride (0.19 ml, 2.4 mmol). The mixture was stirred at room temperature for 2 h and diluted with brine. The mixture was extracted with ethyl acetate. The organic extracts were washed with brine, dried (MgSO 4 ), filtered and concentrated under reduced pressure to afford the mesylate 12 (520 mg, 83%) as a white solid.
1 H-NMR (CDCl 3 ) d: 0.41-0.50 (4H, m, cyclo-Pr CH 2 ϫ2), 1.64-1.86 (5H, m, piperidine 3-CH and 5-CH, HO-CH 2 CH 2 CH 2 -, cyclo-Pr CH), 2.12-2.22 (2H, m, piperidine 3-CH and 5-CH), 2.38 (2H, m, piperidine 2-CH and 6-CH), 3.05 (3H, s, CH 3 SO 2 -), 3.06-3.15 (2H, m, piperidine 2-CH and 6-CH), 3.57-3.72 (6H, m, MsO-CH 2 CH 2 CH 2 -, imidazolidine ring CH 2 ϫ2), 4.22 (1H, m, piperidine 4-CH), 4.34 (2H, t, Jϭ5.8 Hz, MsO-CH 2 CH 2 CH 2 -).
Step e The mesylate 12 (0.21 g, 0.52 mmol) was dissolved in 1,4-dioxane (12 ml), and K 2 CO 3 (145 mg, 1.04 mmol) and piperidine (0.104 ml, 1.04 mmol) were added. After the solution was stirred at 80°C for 15 h, the mixture was allowed to cool to room temperature and diluted with brine. The mixture was extracted with ethyl acetate and the combined organic extracts washed with brine, dried (MgSO 4 ), filtered and concentrated in vacuo. The residue was recrystallized from n-hexane and ethyl acetate to give compound 2c (166 mg, 83%). mp 104-105°C. 
Synthesis of Compounds 2l and 2m (Chart 3)
The following compounds were prepared using a method similar to that of synthesis of com- 
Synthesis of Compound 2h (Chart 4).
Step a To an ice-cooled solution of 3 (10.2 g, 59.9 mmol) in THF (68 ml) was added THF solution (10 ml) of N-(3-hydroxypropyl)ethylenediamine (7.24 g, 61.3 mmol). The mixture was stirred at room temperature for 3 h and diluted with ethyl acetate/diisopropyl ether (each 35 ml). This solution was stirred in an ice bath for 1 h and the resulting white precipitate filtered and dried to give compound 13 (9.48 g, 82% Step b To a solution of compound 13 (1.19 g, 6.19 mmol) and K 2 CO 3 (1.71 g, 12.4 mmol) in DMF (12 ml) was added 1-tert-butoxycarbonyl-4-methanesulfonyloxymethylpiperidine 12) (2.94 g, 9.29 mmol) and the mixture was stirred at 80°C for 21 h and 100°C for 25 h. The reaction mixture was diluted with ethyl acetate and washed with brine. The combined organic extracts were dried (MgSO 4 ), filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography, eluting with CH 3 OH/CHCl 3 (from 3 to 8%) to provide compound 14 (1.21 g, 50%). Step c To a solution of compound 14 (600 mg, 1.60 mmol) and triethylamine (0.445 ml, 3.20 mmol) in dichloromethane (6 ml) was added methanesulfonyl chloride (0.186 ml, 2.40 mmol). The mixture was stirred at room temperature for 5 h and diluted with brine. The mixture was extracted with ethyl acetate. The combined organic extracts were washed with brine and dried (MgSO 4 ), filtered, and concentrated under vacuum to give {1-[[1-(tert-butoxycarbonyl)piperidin-4-yl]methyl]-3-(3-methanesulfonyloxypropyl)imidazolidine-2-ylidene}malononitrile (700 mg, 97%). The mesylate (780 mg, 1.67 mmol) was dissolved in 1,4-dioxane (8 ml), and KI (415 mg, 2.50 mmol) and piperidine (0.496 ml, 5.01 mmol) were added. After the solution was stirred at 80°C for 2.5 h, the mixture was allowed to cool to room temperature and diluted with brine. The mixture was extracted with ethyl acetate and the combined organic extracts were washed with brine, dried (MgSO 4 ), filtered and concentrated under reduced pressure. The residue was chromatographed on silica gel (from 1 to 15% CH 3 3.28-3.50 (2H, m, piperidino-CH 2 -CH 2 -CH 2 -), 3.55-3.70 (6H, m, 4-piperidinyl-CH 2 -, imidazolidine ring CH 2 ϫ2), 4.08-4.24 (2H, m, 2-CH and 6-CH of piperidine).
Step d To a solution of compound 15 (72 mg, 0.16 mmol) in methylene chloride (2 ml) was added trifluoroacetic acid (1 ml) and the mixture was stirred at room temperature for 0.5 h. The reaction mixture was concentrated in vacuo and the residue dissolved in DMF (2 ml). K 2 CO 3 (110 mg, 0.800 mmol) and 2-iodopropane (0.031 ml, 0.32 mmol) were added to the solution and stirred at 50°C for 5 h. The reaction mixture was diluted with ethyl acetate and washed with brine. The combined organic extracts were dried (MgSO 4 ), filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography, eluting with 20% 2 mol/l NH 3 -CH 3 OH/CHCl 3 to yield compound 2h (13 
Synthesis of Compound 2i (Chart 5).
Step a To a solution of compound 10 (HCl salt; 6.36 g, 20.4 mmol) in DMF (50 ml) were added K 2 CO 3 (14.1 g, 102 mmol) and 2-iodopropane (6.1 ml, 61.2 mmol). After the mixture was stirred at 60°C for 23 h, the reaction mixture was diluted with ethyl acetate and washed with brine. The organic extracts were dried (MgSO 4 ), filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography, eluting with 10% CH 3 OH/CHCl 3 to yield compound 16 (1.96 g, 30%) as a pale yellow solid.
